Effects of long-term treatment with transcranial pulsed electromagnetic fields in Parkinson's disease on kinematic and electrophysiological tremor.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41819015.
- Also identified by DOI 10.1016/j.clinbiomech.2026.106808.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Previous studies of the use of transcranial pulsed electromagnetic fields (T-PEMF) as a treatment for Parkinson's disease (PD) for a short period have shown positive results. The aim was to investigate the effect of long-term treatment with T-PEMF on tremor quantified by forearm muscle activation and hand acceleration in PD. Patients (n = 14) received three 8-week periods of daily T-PEMF treatment (±50 V, 3 ms, 55 Hz, 30 min/day). Furthermore, a control group with PD (n = 8, no treatment) and a healthy reference group (n = 5) participated. The participants performed a postural task (3x1min) sitting with arms extended, horizontal, and parallel. Electrophysiological (surface electromyography (EMG) theta-band power in the tremor frequency area, 4-8 Hz) and kinematic tremor (accelerometer tremor intensity, 3-9 Hz) analyses were performed at baseline, week 17 and week 27. At baseline, the PD patients (n = 22, all patients) had consistently significantly higher levels of EMG theta-band power and tremor intensity in the most affected side compared to the healthy reference group. The T-PEMF treatment decreased the median EMG theta-band power (most affected side) consistently, with a statistically significant decrease in flexor muscles and a tendency in extensor muscles. Furthermore, the T-PEMF-treatment decreased median tremor intensity statistically (both sides). In contrast, the PD control group did not change statistically (most affected side) from baseline to week 27. Long-term treatment with T-PEMF changed forearm EMG power and hand acceleration in the tremor frequency spectrum towards healthy values. Thus, the present results add further knowledge to the effects of T-PEMF treatment in PD.